Compugen Ltd.

Regulatory Filings • Mar 26, 2025

FOR IMMEDIATE RELEASE

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

HOLON, ISRAEL, March 26, 2025 - Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming virtual investor conferences in April 2025:

H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development Conference

Date: Wednesday, April 2, 2025 Format: Fireside chat and 1x1 meetings Fireside chat time: 9:30 am ET

24th Annual Needham Virtual Healthcare Conference

Date: Monday, April 7, 2025 Format: Fireside chat and 1x1 meetings Fireside chat time: 8:00 am ET

Stifel's 2025 Virtual Targeted Oncology Forum

Date: Wednesday, April 9, 2025 Format: Fireside chat and 1x1 meetings Fireside chat time: 12:00 pm ET

Live webcasts of the fireside chats will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com. Replays will be available following the live events.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (UnigenTM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding

protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to enhance anti-cancer immunity. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:

Yvonne Naughton, Ph.D. Head of Investor Relations and Corporate Communications Email: ir@cgen.com Tel: +1 (628) 241-0071